Brief: Arcutis Presents Late-Breaking Data From Integument-Ped Phase 3 Trial Of Roflumilast Cream
10/03/2024 20:04
March 10 (Reuters) - Arcutis Biotherapeutics Inc
ARQT.O :
* ARCUTIS PRESENTS LATE-BREAKING DATA FROM INTEGUMENT-PED
PHASE 3
TRIAL OF ROFLUMILAST CREAM 0.05% IN ATOPIC DERMATITIS IN
CHILDREN AGES 2 TO 5
* INVESTIGATIONAL ROFLUMILAST CREAM 0.05% MET PRIMARY
ENDPOINT AND
ALL SECONDARY ENDPOINTS
* RESULTS FOR ROFLUMILAST CREAM SHOW CONSISTENT EFFICACY AND
FAVORABLE SAFETY,TOLERABILITY PROFILE FROM INTEGUMENT-1,
INTEGUMENT-2 PIVOTAL TRIALS
Source text for Eikon: ID:nGNX4PLqR5
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf